Skip to content

The Effect of ShotBlocker on Pain and Satisfaction During Measles-Rubella-Mumps Vaccination

The Effect of ShotBlocker on Pain and Satisfaction During Measles-Rubella-Mumps Vaccination

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06762938
Enrollment
60
Registered
2025-01-08
Start date
2024-08-01
Completion date
2024-11-30
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

Objective The aim of this study was to evaluate the effects of ShotBlocker administration during measles-mumps-rubella (MMR) vaccination on infants' pain level and mothers' satisfaction. Method. The study was conducted in a Family Health Center affiliated to the Public Health Directorate of a province in eastern Turkey between August and October 2024 using a randomized controlled experimental design. The study sample consisted of 60 infants who received MMR vaccination (ShotBlocker group: n = 30, control group: n = 30). Infants in the ShotBlocker group received ShotBlocker before vaccine injection, while infants in the control group received only routine vaccine injection. Infant information form, FLACC pain scale and Newcastle Satisfaction with Nursing Care Scale were used for data collection. Ethical principles were followed throughout the study.

Interventions

BEHAVIORALShotBlocker

Apply ShotBlocker

Sponsors

Yuzuncu Yil University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
12 Months to 12 Months
Healthy volunteers
Yes

Inclusion criteria

* He's 12 months old, * MMR vaccine will be administered, * growth-development is normal, * no analgesic medication was given during the day, * at least high school graduate * mothers who volunteered to participate in the study

Exclusion criteria

* Neurological disease, * a chronic disease, * allergy (egg allergy) * infants with symptoms of hyperthermia

Design outcomes

Primary

MeasureTime frameDescription
Face, Legs, Activity, Crying, Consolability Pain Scalapre-test post-test (approximately three months)min-max (0-10), lower score means better result, reduce scale scores

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026